Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

2021387 citationsJournal Articlehybrid Open Access

Authors

Kathleen N. Moore · Gynecologic Oncology Group

Michael A. Bookman · Kaiser Permanente

Jalid Sehouli · Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe

Austin Miller · Roswell Park Comprehensive Cancer Center

Charles Anderson · Willamette Valley Cancer Institute and Research Center

Giovanni Scambia · Istituti di Ricovero e Cura a Carattere Scientifico

Tashanna Myers

Abstract

Current evidence does not support the use of immune checkpoint inhibitors in newly diagnosed OC. Insight from this trial should inform further evaluation of immunotherapy in OC.

Topics & Keywords

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy Renal cell carcinoma treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 39, Issue 17, pp. 1842-1855

DOI: 10.1200/jco.21.00306

Field-Weighted Citation Impact: 55.68